Subsequent Events	3 Months Ended
Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 14. Subsequent Events Merger Agreement with Syros Pharmaceuticals, Inc. On July 3, 2022, TYME entered into the Merger Agreement with Syros and Merger Sub. Upon the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will merge with and into TYME, with TYME continuing as the surviving entity and a wholly owned subsidiary of Syros. At the Effective Time, each share of Tyme Common Stock, issued and outstanding immediately prior to the Effective Time will be converted into the right to receive a number of shares of fully paid and non-assessable shares of Syros Common Stock equal to the Exchange Ratio (as defined in the Merger Agreement). The completion of the Merger is subject to the satisfaction or waiver of certain closing conditions, including the adoption of the Merger Agreement by holders of a majority of the outstanding shares of Tyme Common Stock.

Subsequent Events

3 Months Ended

Jun. 30, 2022

Note 14. Subsequent Events

Merger Agreement with Syros Pharmaceuticals, Inc.

On July 3, 2022, TYME entered into the Merger Agreement with Syros and Merger Sub. Upon the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will merge with and into TYME, with TYME continuing as the surviving entity and a wholly owned subsidiary of Syros. At the Effective Time, each share of Tyme Common Stock, issued and outstanding immediately prior to the Effective Time will be converted into the right to receive a number of shares of fully paid and non-assessable shares of Syros Common Stock equal to the Exchange Ratio (as defined in the Merger Agreement). The completion of the Merger is subject to the satisfaction or waiver of certain closing conditions, including the adoption of the Merger Agreement by holders of a majority of the outstanding shares of Tyme Common Stock.

TYME TECHNOLOGIES, INC. 10-Q